Enlivex Therapeutics (Enlivex Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 01, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-05-01), Enlivex Therapeutics's share price is $1.6601. Enlivex Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.27. Hence, Enlivex Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Enlivex Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

ENLV's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.12
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Enlivex Therapeutics's Cash Flow from Operations per share for the three months ended in Sep. 2023 was $-0.29. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.27.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -16.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 17.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 16.90% per year.

During the past 12 years, Enlivex Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 72.40% per year. The lowest was -308.00% per year. And the median was 12.55% per year.

Enlivex Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Enlivex Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Price-to-Operating-Cash-Flow Chart

Enlivex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Enlivex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Enlivex Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Enlivex Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enlivex Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Price-to-Operating-Cash-Flow falls into.

Enlivex Therapeutics Price-to-Operating-Cash-Flow Calculation

Enlivex Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.6601	/	-1.266
	=

Enlivex Therapeutics's Share Price of today is $1.6601.
Enlivex Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.27.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Enlivex Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

ENLV:Israel 1BT:Germany

Address

14 Einstein Street, Nes Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.